Niagen Bioscience, Inc. NAGE
3.05
0.04
1.33%
as of 25 Sep
- Market cap
- $238.2M
- P/E
- 15.2×
Follow NAGE
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
34.56 | 27.65 | 18.38 | 15.95 |
P/S ratio |
5.97 | 3.89 | 2.70 | 1.96 | |
P/FCF ratio |
35.23 | 38.17 | 35.64 | 22.09 | |
P/Operating CF |
201.61 | 741.64 | (295.17) | 91.28 | |
P/B ratio |
10.53 | 6.58 | 4.28 | 3.07 | |
Price to Tangible BV |
10.57 | 7.11 | 4.59 | 3.28 | |
EV/Sales |
5.46 | 3.40 | 2.20 | 1.45 | |
EV/EBITDA |
33.91 | 25.76 | 20.54 | 16.17 | |
EV/Operating CF |
31.81 | 32.56 | 64.77 | 31.46 | |
EV/FCF |
32.23 | 33.32 | 29.00 | 16.34 | |
Quick Ratio |
3.21 | 3.74 | 3.49 | 5.00 | |
Current Ratio |
4.12 | 4.86 | 4.61 | 6.50 | |
Net Debt/EBITDA |
(14.51) | (15.12) | (35.64) | (67.35) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.61 | 1.48 | 1.33 | 1.30 | |
Operating CF/Net income |
0.81 | 0.16 | (0.19) | 2.88 | |
Capex/Depreciation |
(0.12) | (0.51) | 19.72 | (0.31) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5.28% | 5.05% | 4.71% | 5.08% | |
Selling, General and Administrative Expense of Revenue |
46.78% | 52.87% | 53.76% | 57.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
5.17% | 5.17% | 5.45% | 5.78% | |
Graham Net Nets |
0.09 | 0.13 | 0.21 | 0.29 | |
Graham Number |
2.32 | 2.24 | 2.36 | 2.16 | |
Earnings Yield |
2.89% | 3.62% | 5.44% | 6.27% | |
Free Cash Flow Yield |
2.84% | 2.62% | 2.81% | 4.53% | |
Revenue per Share |
0.43 | 0.43 | 0.39 | 0.38 | |
Operating CF per Share |
0.05 | 0.01 | (0.01) | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.07 | 0.00 | |
Free Cash Flow per Share |
0.05 | 0.01 | 0.06 | 0.03 | |
Cash per Share |
0.81 | 0.82 | 0.83 | 0.84 | |
Shareholders Equity per Share |
0.89 | 0.97 | 1.03 | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 0.97 | 1.03 | 1.04 | |
Free Cash Flow |
3.67 | 0.58 | 4.55 | 2.68 | |
Working Capital |
70.90 | 76.89 | 82.30 | 82.74 | |
Capital Expenditures |
(0.02) | (0.10) | 5.74 | (0.09) | |
Net Current Asset Value |
66.15 | 66.93 | 73.12 | 73.73 | |
EV/EBIT |
35.27 | 27.01 | 21.92 | 17.66 | |
Capex to Sales |
0.00 | 0.00 | (0.18) | 0.00 | |
Net Profit Margin |
13.47% | 12.21% | 20.07% | 3.23% | |
Price to Operating Income |
38.56 | 30.93 | 26.94 | 23.88 | |
| Other line items | |||||
Average Receivables |
7.80 | 8.75 | 10.06 | 9.12 | |
Average Payables |
9.82 | 9.66 | 11.95 | 11.56 | |
Average Inventory |
14.67 | 14.81 | 17.60 | 17.52 | |
Average Assets |
77.33 | 87.34 | 97.83 | 99.06 | |
Average Common Equity |
52.52 | 61.31 | 68.84 | 73.36 |
Columns are period end dates